Rochelle P Walensky1, Tim Horn2, Nicole C McCann3, Kenneth A Freedberg4, A David Paltiel5. 1. Medical Practice Evaluation Center, Massachusetts General Hospital, Harvard University Center for AIDS Research, Harvard Medical School, Boston, Massachusetts (R.P.W.). 2. National Alliance of State and Territorial AIDS Directors, Washington, DC (T.H.). 3. Massachusetts General Hospital, Boston, Massachusetts (N.C.M.). 4. Massachusetts General Hospital and Harvard University Center for AIDS Research, Harvard Medical School, Boston, Massachusetts (K.A.F.). 5. Yale School of Public Health, New Haven, Connecticut (A.D.P.).
Abstract
Background: Tenofovir alafenamide-emtricitabine (F/TAF) was recently approved as a noninferior and potentially safer option than tenofovir disoproxil fumarate-emtricitabine (F/TDF) for HIV preexposure prophylaxis (PrEP) in the United States. Objective: To estimate the greatest possible clinical benefits and economic savings attributable to the improved safety profile of F/TAF and the maximum price payers should be willing to pay for F/TAF over generic F/TDF. Design: Cost-effectiveness analysis. Data Sources: Published literature on F/TDF safety (in persons with and those without HIV) and the cost and quality-of-life effects of fractures and end-stage renal disease (ESRD). Target Population: Age-stratified U.S. men who have sex with men (MSM) using PrEP. Time Horizon: Five years. Perspective: Health care sector. Intervention: Preexposure prophylaxis with F/TAF versus F/TDF. Outcome Measures: Fractures averted, cases of ESRD averted, quality-adjusted life-years (QALYs) saved, costs, incremental cost-effectiveness ratios (ICERs), and maximum justifiable price for F/TAF compared with generic F/TDF. Results of Base-Case Analysis: Over a 5-year horizon, compared with F/TDF, F/TAF averted 2101 fractures and 25 cases of ESRD for the 123 610 MSM receiving PrEP, with an ICER of more than $7 million per QALY. At a 50% discount for generic F/TDF ($8300 per year) and a societal willingness to pay up to $100 000 per QALY, the maximum fair price for F/TAF was $8670 per year. Results of Sensitivity Analysis: Among persons older than 55 years, the ICER for F/TAF remained more than $3 million per QALY and the maximum permissible fair price for F/TAF was $8970 per year. Results were robust to alternative time horizons and PrEP-using population sizes. Limitation: Intermittent use and on-demand PrEP were not considered. Conclusion: In the presence of a generic F/TDF alternative, the improved safety of F/TAF is worth no more than an additional $370 per person per year. Primary Funding Source: National Institute of Allergy and Infectious Diseases, National Institute on Drug Abuse, National Institute of Mental Health, and Massachusetts General Hospital Executive Committee on Research.
Background: Tenofovir alafenamide-emtricitabine (F/TAF) was recently approved as a noninferior and potentially safer option than tenofovir disoproxil fumarate-emtricitabine (F/TDF) for HIV preexposure prophylaxis (PrEP) in the United States. Objective: To estimate the greatest possible clinical benefits and economic savings attributable to the improved safety profile of F/TAF and the maximum price payers should be willing to pay for F/TAF over generic F/TDF. Design: Cost-effectiveness analysis. Data Sources: Published literature on F/TDF safety (in persons with and those without HIV) and the cost and quality-of-life effects of fractures and end-stage renal disease (ESRD). Target Population: Age-stratified U.S. men who have sex with men (MSM) using PrEP. Time Horizon: Five years. Perspective: Health care sector. Intervention: Preexposure prophylaxis with F/TAF versus F/TDF. Outcome Measures: Fractures averted, cases of ESRD averted, quality-adjusted life-years (QALYs) saved, costs, incremental cost-effectiveness ratios (ICERs), and maximum justifiable price for F/TAF compared with generic F/TDF. Results of Base-Case Analysis: Over a 5-year horizon, compared with F/TDF, F/TAF averted 2101 fractures and 25 cases of ESRD for the 123 610 MSM receiving PrEP, with an ICER of more than $7 million per QALY. At a 50% discount for generic F/TDF ($8300 per year) and a societal willingness to pay up to $100 000 per QALY, the maximum fair price for F/TAF was $8670 per year. Results of Sensitivity Analysis: Among persons older than 55 years, the ICER for F/TAF remained more than $3 million per QALY and the maximum permissible fair price for F/TAF was $8970 per year. Results were robust to alternative time horizons and PrEP-using population sizes. Limitation: Intermittent use and on-demand PrEP were not considered. Conclusion: In the presence of a generic F/TDF alternative, the improved safety of F/TAF is worth no more than an additional $370 per person per year. Primary Funding Source: National Institute of Allergy and Infectious Diseases, National Institute on Drug Abuse, National Institute of Mental Health, and Massachusetts General Hospital Executive Committee on Research.
Authors: Rabi Yacoub; Girish N Nadkarni; Damian Weikum; Ioannis Konstantinidis; Anna Boueilh; Robert M Grant; Kenneth K Mugwanya; Jared M Baeten; Christina M Wyatt Journal: J Acquir Immune Defic Syndr Date: 2016-04-01 Impact factor: 3.731
Authors: Anju Parthan; Morgan Kruse; Nicole Yurgin; Joice Huang; Hema N Viswanathan; Douglas Taylor Journal: Appl Health Econ Health Policy Date: 2013-10 Impact factor: 2.561
Authors: Dawn K Smith; Michelle Van Handel; Richard J Wolitski; Jo Ellen Stryker; H Irene Hall; Joseph Prejean; Linda J Koenig; Linda A Valleroy Journal: MMWR Morb Mortal Wkly Rep Date: 2015-11-27 Impact factor: 17.586
Authors: Alexa B D'Angelo; Drew A Westmoreland; Pedro B Carneiro; Jeremiah Johnson; Christian Grov Journal: AIDS Patient Care STDS Date: 2021-08 Impact factor: 5.944
Authors: Sheree R Schwartz; Joel Chavez Ortiz; Justin D Smith; Laura K Beres; Aaloke Mody; Ingrid Eshun-Wilson; Nanette Benbow; Deepthi P Mallela; Stephen Tan; Stefan Baral; Elvin Geng Journal: J Acquir Immune Defic Syndr Date: 2022-07-01 Impact factor: 3.771
Authors: Anne M Neilan; Raphael J Landovitz; Mylinh H Le; Beatriz Grinsztejn; Kenneth A Freedberg; Marybeth McCauley; Nattanicha Wattananimitgul; Myron S Cohen; Andrea L Ciaranello; Meredith E Clement; Krishna P Reddy; Emily P Hyle; A David Paltiel; Rochelle P Walensky Journal: Ann Intern Med Date: 2022-02-01 Impact factor: 51.598
Authors: Karishma Srikanth; Amy Killelea; Andrew Strumpf; Edwin Corbin-Gutierrez; Tim Horn; Kathleen A McManus Journal: Am J Public Health Date: 2022-04-14 Impact factor: 11.561